MA33808B1 - Formulation pharmaceutique parentérale en suspension, à libération soutenue, à dosage faible et ultra-faible, utilisée dans l'hormonothérapie du syndrome ménopausique - Google Patents

Formulation pharmaceutique parentérale en suspension, à libération soutenue, à dosage faible et ultra-faible, utilisée dans l'hormonothérapie du syndrome ménopausique

Info

Publication number
MA33808B1
MA33808B1 MA34946A MA34946A MA33808B1 MA 33808 B1 MA33808 B1 MA 33808B1 MA 34946 A MA34946 A MA 34946A MA 34946 A MA34946 A MA 34946A MA 33808 B1 MA33808 B1 MA 33808B1
Authority
MA
Morocco
Prior art keywords
low
particles
ultra
secretion
dose
Prior art date
Application number
MA34946A
Other languages
Arabic (ar)
English (en)
Inventor
Uribe Juan Ángeles
Vilboeuf John Claude Savoir
Original Assignee
Techsphere S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44167908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33808(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Techsphere S A De C V filed Critical Techsphere S A De C V
Publication of MA33808B1 publication Critical patent/MA33808B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE FORMULATION OU COMPOSITION PHARMACEUTIQUE PARENTÉRALE, EN SUSPENSION, À LIBÉRATION SOUTENUE, QUI CONTIENT DES PARTICULES EN SUSPENSION D'OESTRADIOL ET DE PROGESTÉRONE POUR LA SUBSTITUTION HORMONALE CHEZ LES MAMMIFÈRES FEMELLES À DOSAGE FAIBLE ET ULTRAFAIBLE. LA FORMULATION EST CONSTITUÉE D'UNE SUSPENSION INJECTABLE COMPOSÉE DE PARTICULES D'OESTRADIOL, DE PARTICULES DE PROGESTÉRONE, D'UN AGENT TENSIO-ACTIF, D'UN AGENT ISOSMOTIQUE, D'UN AGENT AMÉLIORANT LA VISCOSITÉ ET D'AU MOINS UN CONSERVATEUR, LEDIT OESTRADIOL SE TROUVANT DANS DES PARTICULES D'UNE GROSSEUR COMPRISE ENTRE 1 ET 100 MICRONS ET LA PROGESTÉRONE SE TROUVANT DANS DES PARTICULES D'UNE GROSSEUR COMPRISE ENTRE 1 ET 100 MICRONS. CETTE FORMULATION OU COMPOSITION EST DESTINÉE À ÊTRE UTILISÉE DANS LA FORME PHARMACEUTIQUE PARENTÉRALE, INTRAMUSCULAIRE, SOUS-CUTANÉE OU INTRADERMIQUE.
MA34946A 2009-12-15 2012-06-07 Formulation pharmaceutique parentérale en suspension, à libération soutenue, à dosage faible et ultra-faible, utilisée dans l'hormonothérapie du syndrome ménopausique MA33808B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2009013768 2009-12-15
PCT/MX2010/000154 WO2011074931A2 (fr) 2009-12-15 2010-12-14 Formulation pharmaceutique parentérale en suspension, à libération soutenue, à dosage faible et ultra-faible, utilisée dans l'hormonothérapie du syndrome ménopausique

Publications (1)

Publication Number Publication Date
MA33808B1 true MA33808B1 (fr) 2012-12-03

Family

ID=44167908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34946A MA33808B1 (fr) 2009-12-15 2012-06-07 Formulation pharmaceutique parentérale en suspension, à libération soutenue, à dosage faible et ultra-faible, utilisée dans l'hormonothérapie du syndrome ménopausique

Country Status (34)

Country Link
EP (1) EP2520301B2 (fr)
JP (1) JP5900925B2 (fr)
KR (1) KR101758407B1 (fr)
CN (1) CN102655867B (fr)
AR (1) AR079453A1 (fr)
AU (1) AU2010330982B2 (fr)
BR (1) BR112012013823B1 (fr)
CA (1) CA2781999C (fr)
CL (1) CL2012001516A1 (fr)
CO (1) CO6551723A2 (fr)
CY (1) CY1119169T1 (fr)
DK (1) DK2520301T4 (fr)
EC (1) ECSP12011934A (fr)
ES (1) ES2629204T5 (fr)
HR (1) HRP20170962T4 (fr)
HU (1) HUE035223T2 (fr)
IL (1) IL220422A (fr)
LT (1) LT2520301T (fr)
MA (1) MA33808B1 (fr)
MX (1) MX2012006604A (fr)
MY (1) MY163619A (fr)
NZ (1) NZ600539A (fr)
PE (1) PE20130015A1 (fr)
PL (1) PL2520301T5 (fr)
PT (1) PT2520301T (fr)
RS (1) RS56142B2 (fr)
RU (1) RU2582272C2 (fr)
SG (1) SG181723A1 (fr)
SI (2) SI2520301T1 (fr)
SM (1) SMT201700318T1 (fr)
UA (1) UA108865C2 (fr)
UY (1) UY33103A (fr)
WO (1) WO2011074931A2 (fr)
ZA (1) ZA201203992B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2017105512A1 (fr) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations et procédés de commande du cycle de reproduction et de l'ovulation
WO2026015620A1 (fr) 2024-07-09 2026-01-15 Farmastar Llc Formulations pharmaceutiques stables de progestogènes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733407A (en) 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
US4425339A (en) 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US4945103A (en) 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) † 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
SE9403389D0 (sv) * 1994-10-06 1994-10-06 Astra Ab Pharmaceutical composition containing derivattves of sex hormones
US5514382A (en) 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
EP1052980A1 (fr) * 1998-10-09 2000-11-22 PHARMACIA & UPJOHN COMPANY Acetate de medroxyprogesterone administre par voie sous-cutanee en vue du traitement de la menopause et de l'endometriose
AU5181200A (en) * 1999-06-04 2000-12-28 General Hospital Corporation, The Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
CA2528545C (fr) * 2003-06-13 2014-08-12 John Claude Savoir Formulation pharmaceutique pour la contraception et le traitement hormonal substitutif
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico

Also Published As

Publication number Publication date
RU2582272C2 (ru) 2016-04-20
PL2520301T5 (pl) 2021-07-05
WO2011074931A2 (fr) 2011-06-23
MX2012006604A (es) 2012-08-17
HRP20170962T4 (hr) 2021-07-09
CA2781999A1 (fr) 2011-06-23
RS56142B1 (sr) 2017-10-31
WO2011074931A3 (fr) 2011-09-22
UY33103A (es) 2011-07-29
KR20120114269A (ko) 2012-10-16
BR112012013823B1 (pt) 2021-05-25
AR079453A1 (es) 2012-01-25
LT2520301T (lt) 2017-07-25
SI2520301T1 (sl) 2017-07-31
CY1119169T1 (el) 2018-02-14
ECSP12011934A (es) 2012-07-31
JP5900925B2 (ja) 2016-04-06
PL2520301T3 (pl) 2017-10-31
IL220422A (en) 2017-01-31
AU2010330982A1 (en) 2012-07-05
JP2013513658A (ja) 2013-04-22
UA108865C2 (uk) 2015-06-25
PT2520301T (pt) 2017-06-30
EP2520301B1 (fr) 2017-05-10
ES2629204T3 (es) 2017-08-07
EP2520301B2 (fr) 2021-03-03
HUE035223T2 (hu) 2018-05-02
DK2520301T4 (da) 2021-06-07
AU2010330982B2 (en) 2015-05-21
EP2520301A2 (fr) 2012-11-07
SMT201700318T1 (it) 2017-09-07
KR101758407B1 (ko) 2017-07-14
ES2629204T5 (es) 2021-11-02
PE20130015A1 (es) 2013-01-30
ZA201203992B (en) 2013-02-27
NZ600539A (en) 2014-10-31
HRP20170962T1 (hr) 2017-09-22
CN102655867B (zh) 2015-05-27
CN102655867A (zh) 2012-09-05
SI2520301T2 (sl) 2021-08-31
DK2520301T3 (en) 2017-07-17
BR112012013823A2 (pt) 2018-07-31
IL220422A0 (en) 2012-08-30
SG181723A1 (en) 2012-07-30
RS56142B2 (sr) 2021-07-30
HK1170431A1 (en) 2013-03-01
CO6551723A2 (es) 2012-10-31
EP2520301A4 (fr) 2013-10-23
CA2781999C (fr) 2018-10-23
MY163619A (en) 2017-10-13
CL2012001516A1 (es) 2012-12-21
RU2012126501A (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
EP1790340A3 (fr) Chimotherapie combinée
MXPA04003304A (es) Composiciones liquidas de administracion oral que contienen guaifenesina y un copolimero en bloque de polioxialquileno.
MA33808B1 (fr) Formulation pharmaceutique parentérale en suspension, à libération soutenue, à dosage faible et ultra-faible, utilisée dans l'hormonothérapie du syndrome ménopausique
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
PE20110573A1 (es) Sistema de administracion de drogas que contiene progestina
MA40721B1 (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
TWI746613B (zh) 子宮內膜病症治療劑之用法及用量
AR046601A1 (es) Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias
MA44206B1 (fr) Comprimé orodispersible comprenant estetrol
CL2017003208A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
TNSN07343A1 (fr) Compositions ophtalmologiques et leur mode d'utilisation
MXPA04005053A (es) Metodos y composiciones para tratar lesiones del epitelio respiratorio.
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
ATE521343T1 (de) Im mund zerfallende zusammensetzungen von rasagilin
WO2003022205A3 (fr) Methodes et compositions de traitement de lesions epitheliales vaginales, cervicales et uterines
WO2018068047A8 (fr) Compositions comprenant de la relaxine et leurs méthodes d'utilisation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
Debruyne et al. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia
EP4556025A3 (fr) Formulations de docétaxel
EP4371568A3 (fr) Tensioactifs résistant à la dégradation de lipase destinés à être utilisés dans des formulations thérapeutiques à grandes molécules
Mohamed et al. Histological and Immunohistochemical Study of the Effects of Tramadol Administration on the Ovaries of Adult Albino Rats and the Possible Recovery After its Withdrawal.
MA20150424A1 (fr) Compositions liquides orales pédiatriques contenant du nepadutant
FR3073398B1 (fr) Triterpenes pentacycliques dans le traitement d'une pathologie bucco-dentaire